Skip to content

The prevention and treatment effect of Shenlingbaizhu Powder from the perspective of the mechanism of the occurrence of ovarian hyperstimulation syndrome

The prevention and treatment effect of Shenlingbaizhu Powder from the perspective of the mechanism of the occurrence of ovarian hyperstimulation syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005791
Enrollment
Unknown
Registered
2022-03-31
Start date
2021-08-27
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian hyperstimulation syndrome

Interventions

Intervention group:shen ling bai zhu san
Control group:NO

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 38 Years

Inclusion criteria

Inclusion criteria: ? Patients who may develop OHSS and meet the TCM syndrome differentiation criteria of "deficiency of spleen and kidney" were evaluated during COH; ? For ivF-ET patients aged 20-38 years, ovulation induction is suitable for fresh embryo transfer. ? Patients who signed informed consent and agreed to participate in the clinical trial with good compliance. If the inclusion criteria above are not met, the patient cannot be included.

Exclusion criteria

Exclusion criteria: ? Those who have taken similar drug treatment recently and whose efficacy is difficult to judge, or have a history of drug or alcohol abuse. ? Do not want to cooperate (such as not according to the provisions of the drug and affect the curative effect of qiao break) and mental illness, cognitive disorders. ? Emergency measures must be taken if symptoms worsen. ? Allergic constitution or allergic to a certain component of the drug used in the clinical trial. ? Those who are participating in clinical trials of other drugs. ? Failing to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
vascular endothelial growth factor;inflammatory factor;

Countries

China

Contacts

Public ContactWang Aiai
wangaiaizsy@126.com18665033893

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026